Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Duchenne Muscular Dystrophy Market Size And Revenue Outlook Through 2030
The duchenne muscular dystrophy market size has shown significant growth in recent years. It is anticipated to expand from $1.25 billion in 2025 to $1.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. The growth observed in the past can be attributed to the increasing prevalence of duchenne muscular dystrophy, advancements in molecular biology techniques, rising awareness about rare genetic disorders, the development of early diagnostic tools, and increasing research collaborations between academic and pharmaceutical institutions.
The duchenne muscular dystrophy market is anticipated to show significant expansion in the coming years. It is projected to increase to $1.87 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.5%. This anticipated growth can be attributed to several factors, including the rising adoption of gene therapy, the broadening application of precision medicine, increased financial commitment to rare disease drug development, regulatory inducements for orphan drugs, and the incorporation of digital health technologies into patient care. Prominent developments for the forecast period encompass advancements in gene editing, the establishment of personalized treatment protocols, enhanced funding for rare disease research, the evolution of patient-centric care models, and continued progress in orphan drug development.
Get A Free Sample Report With In-Depth Market Insights:
Duchenne Muscular Dystrophy Market Growth Catalysts And Demand Drivers
The rising occurrence of chronic diseases is projected to drive the growth of the Duchenne muscular dystrophy market in the upcoming period. A chronic disease is defined as a health problem or state characterized by symptoms persisting for at least a year. Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the unique therapeutic requirements of individuals living with this genetic condition, thereby emphasizing the broader importance of personalized medicine in managing and potentially reducing the impact of chronic conditions. For instance, in January 2023, as per the National Library of Medicine, a US-based government agency, the count of individuals in the US aged 50 and older with at least 1 chronic condition is expected to increase to 142.66 million by 2050. Hence, the increasing prevalence of chronic diseases is propelling the expansion of the Duchenne muscular dystrophy market.
Duchenne Muscular Dystrophy Market Segment Landscape: Which Areas Lead Development?
The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs
Duchenne Muscular Dystrophy Market Trends Shaping Long-Term Demand
Leading firms within the Duchenne muscular dystrophy market are implementing technological improvements, including advancements in clinical trial design, with the goal of boosting the efficacy and speed of drug development, improving patient results, and expediting the authorization of novel treatments. This involves the structured planning and organization of a clinical trial to assess a new therapy’s safety and effectiveness, encompassing the establishment of objectives, participant selection, and the definition of methodologies and analyses. As an illustration, in March 2024, the Critical Path Institute (C-Path), a US-based non-profit entity, introduced the DMD Clinical Trial Simulator (CTS). This groundbreaking tool, created by C-Path’s Duchenne Regulatory Science Consortium, is designed to refine the structure of efficacy investigations for DMD treatments. Its primary functionalities encompass sophisticated modeling of functional test outcomes, the capacity to simulate diverse situations, enhanced efficiency in trial planning, and public availability through the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). Consequently, it stands as an important asset for researchers and pharmaceutical enterprises involved in DMD studies.
Duchenne Muscular Dystrophy Market Industry Leaders And Competitive Landscape
Major companies operating in the duchenne muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc., WAVE Life Sciences Ltd.
View The Full Duchenne Muscular Dystrophy Market Report:
Duchenne Muscular Dystrophy Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the Duchenne muscular dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
